This article was originally published in The Gray Sheet
Executive SummaryPrivate placement to institutional health care investors completed July 25 raises $18.5 mil. Leading the investment group was Sofinov, societe financiere d'innovation, Inc., a subsidiary of the Caisse de depot et placement du Quebec. Funds will be used to ramp up marketing of the company's BioZ non-invasive digital cardiac function monitoring system. Investors purchased 3.3 mil. unregistered shares of common stock at $5.59 each. In addition, the company repurchased 400,000 shares from an existing investor, yielding net proceeds of $15.5 mil. Gruntal & Co. and Gerard Klauer Mattison & Co. acted as placement agents
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.